Table 9 Number of administrations for each product
From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Agent | Induction year | Maintenance year | 5 year total |
|---|---|---|---|
Adalimumab | 27 | 26 | 131 |
Etanercept | 64 | 52 | 272 |
Infliximab | 8 | 7 | 36 |
Ustekinumab | 5 | 4 | 22 |